Floatz logo

Therapeutic Asset Ratings

220 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Ethiodized Oil
Gastric Cancer
Teclison Ltd.P2CCC (48)
GELATIN PORCINE SKIN, FORMALIN TREATED
Gastric Cancer
Teclison Ltd.P2CCC (48)
her3-dxd
Gastric Cancer
Daiichi SankyoP2CCC (48)
ibi310
Gastric Cancer
Peking UniversityP2CCC (48)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide
Gastric Cancer
Sichuan Baili Pharmaceutical Co., Ltd.P2CCC (48)
Navicixizumab
Gastric Cancer
OncXerna Theraputics, Inc.P2CCC (48)
Pd-L1 T-Hank
Gastric Cancer
ImmunityBio, Inc.P2CCC (48)
Penpulimab
Gastric Cancer
The Central Hospital of Lishui CityP2CCC (48)
PREDNISONE TABLETS
Gastric Cancer
AstraZenecaP2CCC (48)
Rain-32
Gastric Cancer
Rain Oncology IncP2CCC (48)
Serplulimab
Gastric Cancer
RenJi HospitalP2CCC (48)
Si-B003
Gastric Cancer
Sichuan Baili Pharmaceutical Co., Ltd.P2CCC (48)
Tirapazamine
Gastric Cancer
Teclison Ltd.P2CCC (48)
Vebreltinib
Gastric Cancer
Apollomics Inc.P2CCC (48)
Volrustomig
Gastric Cancer
AstraZenecaP2CCC (48)
Tinengotinib
Gastric Cancer
TransThera Sciences (Nanjing), Inc.P1/2CCC (48)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines.
Gastric Cancer
David WaldP1/2CC (46)
Bms-907351
Gastric Cancer
Anwaar SaeedP1/2CC (46)
Cea Car-T Cells
Gastric Cancer
Chongqing Precision Biotech Co., LtdP1/2CC (46)
Cea-Targeted Car-T
Gastric Cancer
Chongqing Precision Biotech Co., LtdP1/2CC (46)
T-Dxd
Gastric Cancer
Iambic Therapeutics, IncP1/2CC (46)
ab-201
Gastric Cancer
GC Cell CorporationP1/2CC (45)
Capmatinib
Gastric Cancer
Cancer Research UKP2/3CC (45)
Futibatinib
Gastric Cancer
Taiho Pharmaceutical Co., Ltd.P1/2CC (45)
Polyiclc
Gastric Cancer
Mayo ClinicP1/2CC (45)
Showing 51 to 75 of 220 assets
PreviousPage 3 of 9Next